Frontlight ResearchEarly access
Fabry disease trials in United States
5 of 13 trials · From ClinicalTrials.gov, checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 3Taking peopleA Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
- Where
- Atlanta, Birmingham, Chicago, Dallas, Gainesville, Minneapolis, Oakland, Philadelphia
- Age
- 18 years to 60 years
- People
- 16 worldwide
- Run by
- Idorsia Pharmaceuticals Ltd.
See details and how to joinNCT07778667 · EU 2026-525207-27-00 - Phase 3Taking peopleA Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
- Where
- Atlanta, Charlotte, Cincinnati, Fairfax, Minneapolis, Pittsburgh
- Age
- 2 years to 11 years
- People
- 8 worldwide
- Run by
- Amicus Therapeutics
See details and how to joinNCT06904261 - Phase 1/2Taking peopleSafety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease
- Where
- Atlanta, Birmingham, Chicago, Cincinnati, Fairfax, Los Angeles, Minneapolis, New York, Pittsburgh, Salt Lake City
- Age
- 18 years to 65 years
- People
- 20
- Run by
- UniQure Biopharma B.V.
See details and how to joinNCT06270316 - Phase 2/3Taking peopleA Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease
- Where
- Atlanta, Cincinnati, Fairfax, Iowa City, Phoenix, Salt Lake City
- Age
- 2 years to 17 years
- People
- 22 worldwide
- Run by
- Chiesi Farmaceutici S.p.A.
See details and how to joinNCT06328608 · EU 2022-503128-29-00 - Phase 1/2Taking peopleA proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
- Where
- Cincinnati, Fairfax, Kansas City, Los Angeles, Minneapolis, Pittsburgh
- Age
- 18 years and over
- People
- 18 worldwide
- Run by
- GC Biopharma Corp
See details and how to joinNCT06858397